Greenwood Capital Associates’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$922K Buy
82,706
+46,323
+127% +$563K 0.09% 167
2026
Q1
$508K Buy
36,383
+12,164
+50% +$171K 0.06% 201
2025
Q4
$349K Buy
24,219
+7,725
+47% +$116K 0.04% 228
2025
Q3
$263K Buy
+16,494
New +$272K 0.03% 246

Other funds holding BTAL

Greenwood Capital Associates's BTAL Position: Q2 2026 in Review

Greenwood Capital Associates increased its AGF US Market Neutral Anti-Beta Fund (BTAL) stake by 127% in Q2 2026, buying an estimated $563K and bringing the position to 82,706 shares worth $922K. The position accounts for 0.09% of the portfolio, ranked #167.

Greenwood Capital Associates first reported a position in BTAL in Q3 2025 and has held it in 4 quarters since. 93 funds tracked by Wall St. Rank hold BTAL as of Q2 2026.

  • Greenwood Capital Associates held 82,706 shares of AGF US Market Neutral Anti-Beta Fund worth $922K as of Q2 2026.
  • Greenwood Capital Associates bought 46,323 AGF US Market Neutral Anti-Beta Fund shares in Q2 2026, an estimated $563K.
  • AGF US Market Neutral Anti-Beta Fund made up 0.09% of Greenwood Capital Associates's portfolio in Q2 2026, its #167 holding.
  • Greenwood Capital Associates first reported a position in AGF US Market Neutral Anti-Beta Fund in Q3 2025 and has held it in 4 quarters since.
  • 93 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q2 2026.

Based on Greenwood Capital Associates's 13F filing for Q2 2026, filed 28 Jul 2026.